IP20-15: Phase-2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)-Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3 Year Outcomes

IP20-15: Phase-2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)-Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3 Year Outcomes

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!